Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Raised to “Hold” at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) from a sell rating to a hold rating in a report released on Monday,Wall Street Zen reports.

Separately, Weiss Ratings lowered shares of Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.50.

View Our Latest Research Report on ACRV

Acrivon Therapeutics Price Performance

Shares of ACRV opened at $1.98 on Monday. The firm has a market cap of $84.84 million, a P/E ratio of -1.05 and a beta of 1.91. The stock has a 50 day simple moving average of $1.94 and a two-hundred day simple moving average of $1.78. Acrivon Therapeutics has a 1 year low of $1.27 and a 1 year high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07. On average, equities analysts anticipate that Acrivon Therapeutics will post -1.76 earnings per share for the current year.

Insider Transactions at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen sold 14,036 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total transaction of $31,019.56. Following the transaction, the chief executive officer directly owned 2,230,052 shares in the company, valued at $4,928,414.92. This trade represents a 0.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 18,253 shares of company stock worth $38,850. 10.50% of the stock is owned by company insiders.

Institutional Trading of Acrivon Therapeutics

A hedge fund recently bought a new stake in Acrivon Therapeutics stock. Spark Investment Management LLC bought a new position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 28,300 shares of the company’s stock, valued at approximately $50,000. Spark Investment Management LLC owned about 0.07% of Acrivon Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its Acrivon Predictive Precision Oncology (AP3) platform to identify tumor characteristics that may predict a patient’s response to specific targeted therapies.

Acrivon’s lead program is ACR-368, an orally administered small-molecule inhibitor designed to target the checkpoint kinase 1 (CHK1) and WEE1 proteins, which help regulate tumor-cell replication and DNA damage responses.

Featured Articles